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A rapid and sensitive micellar electrokinetic capillary chromatography method with UV photodiode-
array detection was developed for the simultaneous determination of atorvastatin and ezetimibe in 
fixed dose drug combination. Experimental conditions such as buffer concentration and pH, surfactant 
concentration, system temperature, applied voltage, injection parameters were optimized in order to 
improve the efficiency of the separation. The best results were obtained when using fused silica capillary 
(48 cm length X 50 µm ID) and 25 mM borate buffer electrolyte at pH 9.3 containing 25 mM SDS, + 30 
kV applied voltage, 20 ºC system temperature. The separation was achieved in approximately 2 minutes, 
with a resolution of 7.02, the order of migration being atorvastatin followed by ezetimibe. The analytical 
performance of the method was verified with regard to linearity, precision, robustness and the limit of 
detection and quantification were calculated.
Uniterms: Micellar Electrokinetic Capillary Chromatography. Fixed Dose Drug Combination. 
Atorvastatin. Ezetimibe.
INTRODUCTION
Ezetimibe (EZE) and atorvastatin (ATO) are 
two lipid-lowering compounds with complementary 
mechanisms of action (Ballantyne et al. ,  2003). 
ATO, (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-
(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-
3,5-dihydroxyheptanoic acid, lowers plasma cholesterol 
and lipoprotein levels by inhibiting 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase 
and cholesterol synthesis by increasing the number of 
hepatic low-density lipoprotein (LDL) receptors on the 
cell-surface to enhance uptake and catabolism of LDL 
(Malhotra, Goa, 2001). EZE, (3R,4S)-1-(4-fluorophenyl)-
3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-
hydroxyphenyl)azetidin-2-one, acts by decreasing 
cholesterol absorption in the small intestine, leading to 
a decrease in the delivery of intestinal cholesterol to the 
liver. This causes a reduction of hepatic cholesterol stores 
and an increase in clearance of cholesterol from blood (Ara 
et al., 2008). The chemical structures of the two analytes 
ATO and EZE are presented in Figure 1.
Combining the different mechanisms of action of 
these agents appears to provide substantial reductions 
in LDL cholesterol, with additional favorable changes 
in total cholesterol. Clinical studies have shown that co-
administration of ATO and EZE was significantly more 
effective at reducing LDL cholesterol concentrations than 
ATO and EZE alone. EZE co-administered with an HMG-
CoA reductase inhibitor is indicated as adjunctive therapy to 
diet for use in patients with primary hypercholesterolaemia 
who are not appropriately controlled with a statin alone 
(Gagné, Gaudet, Bruckert, 2002).
Taking into consideration the great prevalence 
and importance of fixed dose combination in modern 
therapy, the elaboration of new methods of analysis for 
the simultaneous determination of combined substances 
represents a necessity and also a challenge for analyst.
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Capillary electrophoresis (CE) can be considered 
as an alternative and also a complementary separation 
technique to the more frequently used high performance 
liquid chromatography (HPLC) methods, with advantages 
related to the fast analysis time, high separation efficiency 
and especially to the low consumption of analytes and 
reagents (Morzunova, 2006).
ATO in combination with EZE can be determined 
by UV spectrophotometry, thin layer chromatography 
(TLC) – densitometry (Baghdady et al., 2013), HPLC 
(Sechachalam, Kothapally, 2008; Patel et al., 2012) or 
liquid chromatography – mass spectrometry (LC-MS) 
methods (El-Bagary et al., 2014). Only one CE method 
was found in literature for simultaneous determination of 
ATO and EZE by applying a capillary zone electrophoresis 
(CZE) technique using a background electrolyte solution 
consisting of phosphate buffer (2.5 mM, pH 6.7): methanol 
(70:30 v/v) (AlShehri, 2012). However, a few articles were 
also published describing simultaneous determination 
of another HMG-CoA reductase inhibitor, simvastatin 
and EZE from their combination drug products by CE 
(Dalmora et al., 2008; Yardimci, Özaltin, 2010). 
Our aim was to develop a simple, rapid and efficient 
CE method for the simultaneous determination of EZE 
and ATO under optimized analytical conditions and to 
verify the applicability of the newly developed method 
for determination of the two analytes from fixed dose 
combination product.
MATERIAL AND METHOD
Chemicals
Pharmaceutical grade samples of atorvastatin 
calcium (Morepen Laboratories, New Delhi, India) and 
ezetimibe (MSN Laboratories Ltd., India) were used. 
Sodium tetraborate, sodium dodecyl sulphate (SDS) 
were purchased from Merck (Germany) while methanol 
from LachNer (Czech Republic). All reagents were of 
analytical purity. Purified water was provided by a Milli-Q 
Plus water purification system (Millipore, USA).
The pharmaceutical dosage form used in this study 
was Liptruzet (MSD, UK) containing an EZE/ATO ratio 
of 10/40 mg.
Equipment
The measurements were performed on an Agilent 
1600 CE system equipped with a photodiode array (DAD) 
detector and ChemStation software for data handling. 
Separations were carried out in an uncoated fused-silica 
capillary with a total length of 48 cm (40 cm effective 
length), having an internal diameter of 50 µm (Agilent, 
Germany). Buffer pH was determined using a Terminal 
740 pH–meter (Inolab, Germany).
Electrophoretic procedure
Conditioning of new capillaries was conducted by 
flushing with 0.1 M NaOH for 60 minutes and water for 30 
minutes. Prior to all runs the capillary was preconditioned 
by flushing with 0.1 M NaOH, water and background 
electrolyte (BGE) each for 2 minutes.
Stock solution containing 1 mg mL-1of each analyte 
were prepared in methanol and diluted prior to use with the 
same solvent to the appropriate concentration. Both BGE 
and sample solutions were filtered through a 0.45 μm pore 
size membrane filter and sonicated in an ultrasonic bath 
for 5 minutes prior to use.
In the preliminary analysis we applied some 
“standard” electrophoretic conditions for a CE analysis: 
25 mM buffer concentration, temperature 20 ˚C, applied 
FIGURE 1 - Chemical structures of EZE and ATO.
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voltage + 20 kV, injection pressure x time 50 mbar x 3 
sec, sample concentration 25 µg mL-1. The samples were 
introduced in the system at the anodic end of the capillary 
by hydrodynamic injection. Detection was performed at 
210, 230 and 250 nm, and full spectra of the analytes were 
also stored to facilitate peak identification.
Preparation of pharmaceutical samples
When preparing samples from commercial 
formulations, average weight was calculated by weighing 
10 tablets, the tablets were crushed, mixed and powdered in 
a mortar into a homogenous powder; an amount of powder 
equivalent to the weight of one tablet was dissolved in 100 
mL methanol by sonication for 5 minutes with intermittent 
shaking. The solution was filtered through a 0.45 μm 
syringe filter, centrifuged at 3500 rpm for 10 minutes and 
diluted with methanol to the appropriate concentration. 
The same procedure was applied as in the separation from 
standard solutions.
RESULTS AND DISCUSSION
Optimization of the analytical conditions
The pH value is always a critical selectivity 
parameter for the determination of acidic and basic 
compounds, as it determines the ionization degree of the 
analytes, their electrophoretic mobility and the magnitude 
of the electroosmotic flow (EOF). The effective mobility of 
weak anionic and cationic analytes is strongly dependent 
on their pKa values related to the pH of the running buffer.
Preliminary CZE measurements were attempted 
with different phosphate and borate buffer solutions in a 
pH range between 3 and 11; ATO can be determined over a 
relatively large pH range (5-11) being completely ionized 
in anionic forms in neutral and alkaline pH environments, 
EZE can be determined only in an acidic environment 
while over a pH range between 5 -11 presents no own 
electrophoretic mobility and will be carried by the EOF.
Consequently micellar electrokinetic capillary 
chromatography (MEKC) was applied for the separation 
of the two analytes by adding an anionic surfactant, 
sodium dodecyl sulfate (SDS), to the buffer electrolyte. 
MEKC is based on the addition to the buffer solution 
of a micellar “pseudostationary” phase, which interacts 
with the analytes according to partitioning mechanisms, 
just like in a chromatographic method where the 
“pseudostationary” phase is composed by the surfactant 
added to the buffer solution in a concentration above 
its critical micellar concentration (CMC) and EOF acts 
like a chromatographic “mobile phase”. The separation 
principle of MEKC is based on the differential partition 
of the analytes between micelles and water, as analytes 
which are highly retained by the micelle will have longer 
migration times (Hancu et al., 2013).
The optimization of the electrophoretic separation 
was based on the production of acceptable peak shape, 
resolution and separation time. Optimization of the 
developed method was performed in an univariate manner, 
changing one factor at a time, while keeping the others 
constant, in terms of BGE concentration (25-100 mM), 
BGE pH (8-11), SDS concentration (20-50 mM), applied 
voltage (15-30 kV), capillary cassette temperature (15°C-25 
°C) and injection parameters (25-50 mbar x 1-5 seconds).
The effect of buffer pH was investigated in the 
range 8 – 11 using a 25 mM sodium tetraborate, 25 mM 
SDS buffer; the best correlation between migration times, 
resolution and peak shapes were obtained at pH 9.3.
The effect of running buffer concentration was 
examined by varying it between 25 and 100 mM at a 
constant pH of 9.3. An increase in buffer concentration 
generated higher currents and increased migration time, 
consequently a concentration of 25 mM was chosen in 
order to reduce analysis time.
The effect of surfactant concentration was assessed 
in the range of 20 – 50 mM, the increase of SDS 
concentration resulted in increased migration times, 
consequently the optimum SDS concentration was set to 
25mM. 
The effects of organic modifiers like acetonitrile 
or methanol in the concentration range of 5 – 20%, were 
also evaluated, but only an increase in migration times 
was obtained and no improvement on the electrophoretic 
separation was achieved.
The effect of the separation voltage in the range of 
15–30 kV was examined, high voltage reduces analysis 
time while low voltage enhances separation, a voltage of 
+ 30 kV was selected as the optimum.
The influence of capillary temperature (15-25ºC) 
was evaluated; when temperature increased migration 
times decreased; a temperature of 20ºC was chosen as 
working temperature for the analysis.
In order to determine the optimal injection 
parameters, the influence of injection time (1-5 s) and 
injection pressure (25-50 mbar) were studied. An injection 
pressure of 50 mbar and an injection time of 1 second 
proved to be appropriate to attain low detection limit 
without affecting the peak shape, migration time and 
resolution.
The best results for the simultaneous determination 
of ATO and EZE were obtained when using 25 mM borate 
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buffer containing 25 mM SDS at pH 9.3, + 30 kV applied 
voltage, 20ºC system temperature, injection pressure 50 
mbar, injection time 1 second, UV detection at 230 nm. 
The two analytes migrated in less than 2 minutes, the order 
of migration was ATO followed by EZE; the resolution of 
the separation was 7.02 with a selectivity factor of 1.49 
(Figure 2).
Analytical performance
Linearity solutions were prepared from stock 
solution at six concentration levels and three replicates 
per concentration. The linear regression analysis of ATO 
and EZE were constructed by plotting the peak area of 
the analytes (y) versus analytes’ concentration in (x) axis. 
The calibration curves were linear in the studied range 
(5-100 µg mL-1) with correlation coefficients above 0.99. 
The regression equation and correlation coefficients are 
presented in Table I.
The approach based on the standard deviation of the 
response and the slope of the calibration plots was used 
to determine detection (LOD) and quantification (LOQ) 
limits. LOD and LOQ values were estimated as [(standard 
deviation of repeatability)/(slope of the regression 
equation)] by multiplying with 3.3 and 10 respectively. 
The values obtained are given in Table I.
The intra-and inter-day variability or precision 
are summarized in Table II and were assessed by using 
standard solutions prepared to produce solutions of three 
different concentrations of each drug. Repeatability or 
intra-day precision was investigated by injecting six 
replicate at of each of the samples of three different 
concentrations. Inter-day precision were assessed by 
injecting the same three samples over three consecutive 
days.
To demonstrate the robustness of the method, minor 
changes in the experimental conditions were performed; 
as pH of the buffer was varied in the range ± 0.5 pH unit, 
separation temperature in the range ± 2 °C while applied 
voltage in the range ± 2 kV. None of the modifications 
caused significant changes in the resolution. The RSD for 
migration times and peak areas was under 3%.
FIGURE 2 - Capillary electrophoretic separation of atorvastatin (ATO) and ezetimibe (EZE), (experimental conditions: 25 mM 
borate buffer electrolyte at pH 9.3 containing 25 mM SDS, +30 kV applied voltage, 20 ºC system temperature, 50 mbar/s injection 
parameters, UV detection 230 nm).
TABLE I - Analytical parameters for the simultaneous determination of ATO and EZE (n = 6)
Analyte Concentration 
range (μg mL-1) Regression equation
Correlation 
coefficient
LOD 
(μg mL-1)
LOQ 
(μg mL-1)
ATO 5-100 y = 0.8279x + 8.3137 0.9965 0.27 0.89
EZE 5-100 y = 0.9114x + 8.0645 0.9981 1.29 4.31
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The solution stability of ATO and EZE was carried 
out by leaving the test solution in tightly capped volumetric 
flask at room temperature for 24 hours. The sample solution 
was assayed against freshly prepared standard solutions, the 
RSD of the assay of ATO and EZE were within 5% and it 
indicates that both standard and test preparation were stable 
for 24 hours on benchtop at room temperature.
The electropherograms obtained from tablets were 
similar to those obtained from standard solutions. There 
were no interfering peaks of excipients with the analytes. 
The % recovery was found to be in the range of 98 - 102% 
indicating high degrees of accuracy of the proposed 
method (Table III).
CONCLUSION
A MEKC method for the simultaneous determination 
of ATO and EZE was successfully developed. A 
conventional method optimization based on changing 
one variable at a time, while keeping the other variables 
constant was applied in order to establish the optimal 
analytical conditions. Under the optimized conditions, 
baseline separation of the two analytes was obtained in 
approximately 2 minutes. In comparation with the results 
published by AlShehri (2012) much shorter migration 
times and comparable resolution were obtained by 
applying a MEKC technique instead of CZE (2 minutes 
versus 15 minutes).
Good analytical performance with regards to 
linearity, precision, reproductibility and robustness 
was achieved. Furthermore, the proposed method was 
successfully applied for the determination of the analytes 
in their co-formulated tablets. 
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